TRAXENS
11.6.2019 09:02:08 CEST | Business Wire | Press release
Traxens, a company providing high-value data and services for the supply chain industry, today announces it has equipped the smart reefer containers of a leading Indoniesian NVOCC company, PT TKSolusindo, with its patented Traxens solution.
PT TKSolusindo is a major Non-Vessel Operating Common Carrier (NVOCC) in Indonesia, a country made up of 17,000 islands, where domestic container trades are essential in the daily life of inhabitants. The containers, delivered from the Taicang and Qingdao factories of China International Marine Containers (CIMC), were equipped with Traxens’ smart solutions in only a few days. These now bring PT TKSolusindo, and its clients, full visibility of shipped cargo in the controlled-atmosphere containers throughout all logistical legs of the journey.
Traxens’ solution addresses key challenges in the shipping industry faced by both asset owners and cargo owners. With the support of telematics, asset owners can control costs and develop more agile business problem solving, while cargo owners can easily keep track of their containers, bringing improved business processes and decision making capabilities. Reduced operational costs, improved supply chain efficiency, enhanced security and the opportunity to extend offerings to customers are amongst the key benefits gained through Traxens’ smart solutions. The whole shipping ecosystem, including ports, freight forwarders, insurance and financial institutions, can also benefit from the value-added data gathered by Traxens’ cutting-edge technology.
Traxens offers a comprehensive solution for the reefer industry, which comprises the company’s Reefer Fleet Management and Reefer Door-to-door Monitoring cloud-based applications via the Traxens-Hub, which collects data from Traxens-Box devices installed on containers.
“Traxens’s novel technology is a great addition to the services we provide to our customers, who are keen on staying informed about their cargo’s whereabouts and conditions at all times,” said Glenn Manoppo from PT TKSolusindo. “The reasonable and competitive pricing offered by Traxens were important in our decision when selecting the right partner for the digital transformation of our operations.”
“We are delighted that our reefer tracking technology was chosen by PT. TKSolusindo and we believe that our solution will support the company with the digital transformation of its shipping business,” said Jacques Delort, managing director of Traxens. “We look forward to further co-operations in Asia, a region where domestic and international shipping is crucial for economic success.”
Traxens counts major BCOs among its customers; it also partners with major shipping lines in providing bespoke tracking data for containers.
About PT Trans Kontainer Solusindo (TKSolusindo)
PT TKSolusindo is a subsidiary of an Integrated Cold Chain Solution Company of PT. Kiat Ananda Group, who became the first integrated services provider for refrigerated goods in Indonesia.
PT TKSolusindo specializes in domestic inter-island transport using reefer containers to reach other areas in Indonesia to distribute customers’s goods. The company was set up in 2014, and is now the largest NVOCC in Indonesia with major customers, including international brands such as Unilever, Pizza Hut, Starbucks, Yakult Probiotic, Kentucky Fried Chicken, Greenfield Diary, etc. and local brands such as Hypermart Retail, Hero Retail, Transmart Retail, Charoen Pokphand Indonesia etc. PT TKSolusindo manages more than 500 fleets, generators and trucking.
PT TKSolusindo will develop its international forwarding to support the group trading business in the future.
ABOUT TRAXENS
Traxens generates, collects, consolidates, enriches and transforms logistics asset data into actionable insight for its clients in the maritime, rail and supply chain industries.
The company’s breakthrough Internet-of-Big-Things technology provides comprehensive, real-time information for managing logistics assets anywhere in the world. Traxens’ solutions digitally transform multi-modal supply chains, enabling customers to reduce costs, optimize investments, comply with environmental regulations and deliver premium services to their customers. Traxens’ IoT solution received the Frost & Sullivan’s Technology Leadership Award in 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005054/en/
Contact:
PRESS CONTACT : Géraldine Saunière DIRECTOR OF COMMUNICATIONS Mail: g.sauniere@traxens.com Tel: +33 695 915 899
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom